Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 362,266	$ 97,246
Prepaid expenses and other current assets	11,903	2,076
Short term notes receivable	913	0
Short term notes receivable - related party	0	226
Total current assets	375,082	99,548
Property and equipment, net	149	71
Deferred offering costs	0	1,575
Equity Method Investments	16,131	0
Other investments	11,628	8,044
Long term notes receivable	0	911
Long term notes receivable - related parties	3,835	1,060
Other assets	7,341	339
Total assets	414,166	111,548
Current liabilities:
Accounts payable	6,004	3,083
Accrued liabilities	14,829	9,215
Current portion of contingent consideration liability - related parties	51	0
Other current liabilities	51	0
Total current liabilities	20,935	12,298
Non-current portion of contingent consideration liability - related parties	2,432	1,705
Convertible promissory notes - related parties, net of discounts and deferred issuance costs	743	1,199
Convertible promissory notes and derivative liability (including a related party convertible promissory note and derivative liability of $0 million and $0.3 million at December 31, 2021 and December 31, 2020, respectively)	0	978
Other liabilities	4,097	0
Total liabilities	28,207	16,180
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, 0.10 par value ($0.12 par value at December 31, 2021 and December 31, 2020, respectively); 750,000,000 and 173,116,704 shares authorized at December 31, 2021 and December 31, 2020, respectively; 160,677,001 and 114,735,712 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	18,002	13,372
Additional paid-in capital	725,045	261,626
Accumulated other comprehensive income (loss)	(8,336)	5,819
Accumulated deficit	(357,803)	(189,995)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	376,908	90,822
Noncontrolling interests	9,051	4,546
Total stockholders' equity	385,959	95,368
Total liabilities and stockholders' equity	$ 414,166	$ 111,548